Search for "peptides before and after" and the first page is mostly short videos and clinic photo galleries: a face, a waist or a torso, then the same one weeks later. The pictures answer a question nobody can check — did the peptide do that? — and leave out the one people can: how much did the peptide change, measured, against people who got a placebo?
This page answers the second question. It sets out why a photograph cannot carry the claim, what the approved peptides' own labels measured and by how much, and which popular research peptides have no outcome trial at all. When something changes is a separate question with its own page: how long peptides take to work. Nothing here is a recommendation; whether any peptide suits a person is a decision for a clinician.
Why a photo cannot show a result
A before-and-after pair is one person, at two moments, chosen by whoever posted it. Between the two pictures, almost everything that changes how a body looks can move on its own: lighting and camera angle, posture and muscle tension, time of day and hydration, a tan, a haircut, a change of diet or training, ordinary weight change, and editing. There is no placebo group, so nothing separates the peptide from the rest. And the pair shown is the one somebody chose to show.
US advertising law treats this as a claim of typical results. The Federal Trade Commission's Endorsement Guides (16 CFR 255.2, read 14 October 2026) say an advertiser presenting a consumer's experience needs substantiation that it represents what consumers generally achieve — and that a line such as "results not typical" does not by itself make an unrepresentative testimonial acceptable. A clinic gallery is advertising; it is a selected case, not a measurement.
What the approved peptides measured
Approved peptide drugs have what photographs lack: a pre-specified outcome, measured the same way in hundreds of people, against placebo. These are the effect sizes their US labels print:
| Peptide (brand) | Who was studied | Outcome measured | Peptide | Placebo | Label |
|---|---|---|---|---|---|
| Tesamorelin (EGRIFTA) | 806 adults with HIV and abdominal fat, two trials | Visceral fat on CT at 26 weeks | −18% / −14% | +2% / −2% | EGRIFTA WR, rev. 3/2025 |
| Tesamorelin, same trials | Body weight | −0.4 / +0.5 kg | 0.0 / +0.3 kg | same | |
| Teriparatide (FORTEO) | Postmenopausal women with osteoporosis (541 vs 544) | Lumbar spine bone density, median 19 months | +9.7% | +1.1% | FORTEO, eff. 2026-08-03 |
| Teriparatide, same trial | 444 vs 448 with spine X-rays | Women with ≥1 new vertebral fracture | 5.0% | 14.3% | same |
| Bremelanotide (VYLEESI) | 1,267 premenopausal women with low sexual desire (HSDD), two 24-week trials | Desire score (scale 1.2–6), change | +0.5 / +0.6 | +0.2 / +0.2 | VYLEESI, eff. 2025-11-13 |
Three things stand out once the numbers sit in a table.
The changes are specific. Tesamorelin reduced fat inside the abdomen and left body weight unchanged — the label says it "is not indicated for weight loss management." A photo of a flatter stomach would not distinguish that from weight loss, and the trials say weight loss is not what happened. The full record is on our tesamorelin results page.
Some changes are invisible. Teriparatide's result is bone density on a scan and fewer spine fractures on X-ray — 9.3 fewer women in every 100 with a new vertebral fracture. Nothing in a mirror shows it, and it is one of the best-measured peptide results there is.
Some changes are modest. Bremelanotide's desire score rose about 0.3 to 0.4 points more than placebo on a scale that runs from 1.2 to 6. That was enough for approval, and it is a real difference measured in more than 1,200 women — and it is a fraction of the change a testimonial would describe. Placebo groups improve too, which is why the comparison matters. How that change compares with the label's own responder threshold, and how many women left the trials early, is on our Vyleesi trial record for women.
Approved peptides are listed, with their indications, on our FDA-approved peptides page. Skin peptides used in creams are a different literature, covered by PeptideGlowJournal, including its page on glow peptide before-and-after claims.
GLP-1 drugs are the exception, and have their own record
Semaglutide and tirzepatide are peptides with large, long weight trials, so their labels print average weight change against placebo. That record — and the photographs that circulate for it — is covered by GLP1 Ledger's GLP-1 before and after page, and it is not repeated here. The rest of this page concerns peptides that have no such trial.
Research peptides: the documented absence
Most peptides sold for "research use" and promoted for healing, fat loss or recovery were never put through a human outcome trial for those claims. We searched PubMed on 14 October 2026:
| Peptide | Records on PubMed | Randomised human outcome trials of the marketed use | What the human record is |
|---|---|---|---|
| BPC-157 | 231 | 0 tagged as a randomised controlled trial | Animal studies; small uncontrolled reports — see BPC-157 side effects |
| MOTS-c | 258 | 0 giving MOTS-c to people | The body's own MOTS-c measured around exercise; one 4-week trial of an analogue — see MOTS-c results |
| CJC-1295 | 2 clinical-trial records | 0 measuring body composition | Two 2006 studies of GH and IGF-1 levels in healthy adults |
| TB-500 | 7 trial records for thymosin beta-4 | 0 of TB-500 itself | Trials used full-length thymosin beta-4 (eye, heart, wound studies), a different molecule from the fragment sold as TB-500 |
| Ipamorelin | 2 clinical-trial records | 0 measuring body composition | A 1999 pharmacology study; a 2014 trial in postoperative bowel recovery |
An empty column is a finding, not a gap in our search. It means the photographs and timelines attached to these peptides rest on no controlled measurement, and that whether they produce the advertised change in people is unknown — not disproven, unknown. Several have FDA reviews from 2026 that say the same in regulatory language; our are peptides safe page collects them.
Where clinic timelines come from
The answers search engines summarise for this query often sort results by goal — skin, weight, muscle, recovery — and attach week ranges to each. For approved drugs, the honest version of a timeline is the label's measurement schedule. For the peptides in the second table, there is no trial schedule to draw on, so a week range attached to them is a clinic's or seller's claim, and should be read as one. Sermorelin, which had a label before it was discontinued, sits in between; its measured record is on our sermorelin results page.
How to read any "results" claim
A short set of questions separates a result from a picture:
- Was there a comparison group? Without placebo, nothing separates the peptide from time, diet and training.
- What was measured, and was it chosen in advance? CT-measured fat, bone density and fracture counts are outcomes; "looks leaner" is not.
- How many people, for how long? One person for six weeks is an anecdote.
- Who published it, and do they sell it? A selected case from a seller is advertising.
- Is it the same molecule? Trials of thymosin beta-4 are not trials of TB-500; trials of an analogue are not trials of the parent peptide.
For the wider context of what peptide therapy is and how it is offered, see our peptide therapy explainer.